Table 1.
Patient- and tumor characteristics for women with primary breast cancer stage I–III diagnosed 1992–2005, by age at diagnosis (N = 1120)
| <35 years | 35–39 years | 40–49 years | 50–69 years | |||||
|---|---|---|---|---|---|---|---|---|
| n = 445 | n = 190 | n = 192 | n = 293 | |||||
| No. | (%) | No. | (%) | No. | (%) | No. | (%) | |
| Year of diagnosis | ||||||||
| 1992–1997 | 169 | (38.0) | 82 | (43.2) | 86 | (44.8) | 89 | (30.4) |
| 1998–2002 | 175 | (39.3) | 61 | (32.1) | 62 | (32.3) | 132 | (45.1) |
| 2003–2005 | 101 | (22.7) | 47 | (24.7) | 44 | (22.9) | 72 | (24.6) |
| Detection by screening | 6 | (1.3) | 5 | (2.6) | 45 | (23.4) | 167 | (57.0) |
| Hereditya | ||||||||
| Any heredity | 187 | (42.0) | 73 | (38.4) | 59 | (30.7) | 80 | (27.3) |
| ≥1 first grade relative | 81 | (18.2) | 37 | (19.5) | 25 | (13.0) | 50 | (17.1) |
| Tumor size | ||||||||
| 1–10 mm | 67 | (15.1) | 27 | (14.2) | 35 | (18.2) | 77 | (26.3) |
| 11–20 mm | 148 | (33.3) | 72 | (37.9) | 80 | (41.7) | 136 | (46.4) |
| 21–50 mm | 189 | (42.5) | 72 | (37.9) | 70 | (36.5) | 67 | (22.9) |
| >51 mm | 38 | (8.5) | 16 | (8.4) | 6 | (3.1) | 11 | (3.8) |
| Missing | 3 | (0.7) | 3 | (1.6) | 1 | (0.5) | 2 | (0.7) |
| Lymph node status | ||||||||
| Node neg | 227 | (51.0) | 90 | (47.4) | 116 | (60.4) | 214 | (73.0) |
| 1–3 nodes pos | 126 | (28.3) | 68 | (35.8) | 47 | (24.5) | 57 | (19.5) |
| >4 nodes pos | 92 | (20.7) | 32 | (16.8) | 29 | (15.1) | 22 | (7.5) |
| Stage | ||||||||
| I | 14 | (32.4) | 63 | (33.2) | 87 | (45.3) | 172 | (58.7) |
| IIa | 126 | (28.3) | 50 | (26.3) | 44 | (22.9) | 74 | (25.3) |
| IIb | 71 | (16.0) | 35 | (18.4) | 28 | (14.6) | 21 | (7.2) |
| III | 103 | (23.1) | 40 | (21.1) | 33 | (17.2) | 26 | (8.9) |
| Unstaged | 1 | (0.2) | 2 | (1.1) | 0 | 0 | ||
| Grade (Elston) | ||||||||
| I | 21 | (5.3) | 21 | (12.7) | 31 | (17.9) | 75 | (27.3) |
| II | 140 | (35.6) | 63 | (38.2) | 79 | (45.7) | 131 | (47.6) |
| III | 232 | (59.0) | 81 | (49.1) | 63 | (36.4) | 69 | (25.1) |
| Missing | 52 | 25 | 19 | 18 | ||||
| Estrogen receptorb | ||||||||
| Pos | 208 | (47.2) | 122 | (64.9) | 146 | (77.7) | 225 | (78.1) |
| Neg | 233 | (52.8) | 66 | (35.1) | 42 | (22.3) | 63 | (21.9) |
| Missing | 4 | 2 | 4 | 5 | ||||
| Progesterone receptorb | ||||||||
| Pos | 155 | (35.4) | 85 | (45.2) | 114 | (60.6) | 145 | (51.1) |
| Neg | 283 | (64.6) | 103 | (54.8) | 74 | (39.4) | 139 | (48.9) |
| Missing | 7 | 2 | 4 | 9 | ||||
| Ki-67 (%) | ||||||||
| Low ≤20 | 70 | (18.8) | 42 | (26.9) | 67 | (40.1) | 127 | (51.2) |
| High >20 | 302 | (81.2) | 114 | (73.1) | 100 | (59.9) | 121 | (48.8) |
| Missing | 73 | 34 | 25 | 45 | ||||
| Her2 | ||||||||
| Neg | 296 | (79.6) | 127 | (81.4) | 150 | (90.4) | 225 | (91.8) |
| Pos | 76 | (20.4) | 29 | (18.6) | 16 | (9.6) | 20 | (8.2) |
| Missing | 73 | 34 | 26 | 48 | ||||
| Subtype | ||||||||
| Luminal A | 27 | (7.7) | 23 | (15.1) | 40 | (25.8) | 59 | (25.9) |
| Luminal B | 132 | (37.5) | 66 | (43.4) | 80 | (51.6) | 117 | (51.3) |
| Luminal-Her2 | 35 | (9.9) | 16 | (10.5) | 7 | (4.5) | 10 | (4.4) |
| Her2-positive | 40 | (11.4) | 13 | (8.6) | 8 | (5.2) | 9 | (3.9) |
| Triple-negative | 118 | (33.5) | 34 | (22.4) | 20 | (12.9) | 33 | (14.5) |
| Unclassified | 93 | 38 | 37 | 65 | ||||
| Presence of: | ||||||||
| LVIb | 139 | (31.2) | 43 | (22.6) | 39 | (20.3) | 32 | (10.9) |
| Invasive multifocality | 96 | (21.6) | 39 | (20.5) | 35 | (18.2) | 46 | (15.7) |
| Extensive DCIS | 92 | (20.7) | 43 | (22.6) | 30 | (15.6) | 37 | (12.6) |
aAny family history of breast or ovarian cancer
bData retrieved by re-evaluation with IHC (ER and PR) or reviewed by a pathologist (LVI). If missing data, information was retrieved from medical records